[2] Plutzky et al. Reductions in lipids and CV risk markers in T2D patients treated with liraglutide: a meta-analysis. 20th World Diabetes Congress 18-22 Oct 2009, Montreal, CAN; Abstract O-0542.
[3] Zinman et al. Impact of liraglutide on reaching target HbA1C without weight gain or hypoglycaemia, versus other T2D therapies. 20th World Diabetes Congress 18-22 Oct 2009, Montreal, CAN; Abstract D-0910.
[4] Buse J et al. A switch from twice-daily exenatide to once-daily liraglutide further improves glycaemic control in patients with type 2 diabetes on oral patients. Diabetologia 2009; 52 (Suppl. 1): Abstract 2.
[5] Buse J, Rosenstock J, Sesti G, Schmidt WE, Montanya E, Brett J, Zychma M, Blonde L for the LEAD 6 study group. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 2009; 374 (9683): 39-47.
Further information: Media: Katrine Sperling, Tel: +45-44426718, krsp@novonordisk.com; In North America: An Phan, Tel: +1-609-558-0420, anph@novonordisk.com; Investors: Mads Veggerby Lausten, Tel: +45-4443-7919, mlau@novonordisk.com; Kasper Roseeuw Poulsen, Tel: +45-4442-4471, krop@novonordisk.com; In North America: Hans Rommer, Tel: +1-609-919-7937, hrmm@novonordisk.com
